¨
|
Preliminary
Information Statement
|
¨
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14c-5(d)(2))
|
x
|
Definitive
Information Statement
|
x
|
No
fee required
|
¨
|
Fee
computed on table below per Exchange Act Rules 14c-5(g) and
0-11
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
||
(2)
|
Aggregate
number of securities to which transaction applies:
|
||
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
|
||
(4)
|
Proposed
maximum aggregate value of transaction:
|
||
(5)
|
Total
fee paid:
|
¨
|
Fee
paid previously with preliminary
materials.
|
¨
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its
filing.
|
(1)
|
Amount
Previously Paid:
|
||
(2)
|
Form,
Schedule or Registration Statement No.:
|
||
(3)
|
Filing
Party:
|
||
(4)
|
Date
Filed:
|
||
/s/ John
McManus
|
John
McManus
|
Chief
Executive Officer
|
January
28, 2010
|
Name
|
Affiliation
|
Shares Beneficially Held
|
Percentage
|
|||||||
Xmark
Opportunity Partners, LLC
|
10%
Shareholder
|
36,620,453 | 67.4 | % |
Name of Nominee
|
Age as of
January 28,
2010
|
Director Since
|
||
David
C. Cavalier
|
40
|
April
2004
|
||
John
M. Farah, Jr., Ph.D.
|
57
|
October
2005
|
||
Joseph
J. Krivulka
|
57
|
June
2004
|
||
Amit
Kumar, Ph.D.
|
45
|
June
2004
|
||
Michael
E. Lewis, Ph.D.
|
58
|
June
2004
|
||
Chris
A. Rallis
|
56
|
June
2004
|
||
Peter
D. Suzdak, Ph.D.
|
51
|
June
2004
|
|
·
|
each person known by Aeolus to
beneficially own more than 5% of the outstanding shares of each class of
the Company’s stock;
|
|
·
|
each of Aeolus’
directors;
|
|
·
|
each of Aeolus’ Named Executive
Officers (as defined under “Executive Compensation” below);
and
|
|
·
|
all of Aeolus’ directors and
executive officers as a
group.
|
Preferred Stock
|
Common Stock
|
|||||||||||||||
Identity of Owner or Group (1)(2)
|
Beneficially
Owned
|
Percentage
Owned
|
Beneficially
Owned
|
Percentage
Owned(4)
|
||||||||||||
Directors:
|
|
|
||||||||||||||
David
C. Cavalier
|
- | - | 92,031,076 | (5) | 88.8 | % | ||||||||||
John
M. Farah, Jr., Ph.D. (6)
|
- | - | 124,092 | * | ||||||||||||
Joseph
J. Krivulka (6)
|
- | - | 130,063 | * | ||||||||||||
Amit
Kumar, Ph.D. (6)
|
- | - | 164,063 | * | ||||||||||||
Michael
E. Lewis, Ph.D. (6)
|
- | - | 140,001 | * | ||||||||||||
Chris
A. Rallis (6)
|
- | - | 164,063 | * | ||||||||||||
Peter
D. Suzdak, Ph.D. (6)
|
- | - | 147,501 | * | ||||||||||||
Named
Executive Officers:
|
||||||||||||||||
Brian
Day, Ph.D. (7)
|
- | - | 435,478 | * | ||||||||||||
John
L. McManus (8)
|
- | - | 1,879,166 | 3.9 | % | |||||||||||
Michael
P. McManus (9)
|
- | - | 394,850 | * | ||||||||||||
All
directors and executive officers as a group (10
persons)
|
- | - | 77,125,309 | (10) | 82.3 | % | ||||||||||
Greater
than 5% Stockholders:
|
||||||||||||||||
Elan
Corporation, plc
|
475,087 | 100.0 | %(3) | 475,087 | (11) | 1.0 | % | |||||||||
Lincoln
House
|
||||||||||||||||
Lincoln
Place
|
||||||||||||||||
Dublin
2, Ireland
|
||||||||||||||||
Efficacy
Biotech Master Fund Ltd
|
- | - | 16,660,000 | (12) | 31.3 | % | ||||||||||
11622
El Camino Real, Suite 100
|
||||||||||||||||
San
Diego, CA 92130
|
||||||||||||||||
Xmark
Opportunity Partners, LLC and its affiliates
|
- | - | 91,858,326 | (13) | 80.5 | % | ||||||||||
90
Grove Street
|
||||||||||||||||
Ridgefield,
CT 06877
|
Fees Earned or
|
All Other
|
|||||||||||||||
Name
|
Paid in Cash
|
Option Awards(1)
|
Compensation
|
Total
|
||||||||||||
David
C. Cavalier
|
— | $ | 25,872 | — | $ | 25,872 | ||||||||||
John
M. Farah, Jr., Ph.D.
|
— | 19,220 | — | 19,220 | ||||||||||||
Joseph
J. Krivulka
|
— | 12,110 | — | 12,110 | ||||||||||||
Amit
Kumar, Ph.D.
|
— | 25,872 | — | 25,872 | ||||||||||||
Michael
E. Lewis, Ph.D.
|
— | 14,725 | — | 14,725 | ||||||||||||
Chris
A. Rallis
|
— | 25,872 | — | 25,872 | ||||||||||||
Peter
D. Suzdak, Ph.D.
|
— | 19,220 | — | 19,220 |
(1)
|
The
amounts in the “Option Awards” column reflect the dollar amounts
recognized as compensation expense for financial statement reporting
purposes for stock options for the fiscal year ended September 30, 2009 in
accordance with SFAS 123(R). The assumptions we used to calculate
these amounts are discussed in Note H to our consolidated financial
statements included in our Annual Report on Form 10-K for the year
ended September 30, 2009.
|
|
·
|
Each
non-executive Board member shall be eligible to receive nonqualified stock
options for up to an aggregate of 45,000 shares per year based upon
the number of meetings attended by the non-executive Board member during
the year. The option exercise prices shall be equal to the
closing price of the Common Stock on the grant date. The options shall
have 10-year terms and vest, as long as the director remains on the Board,
on a monthly basis over a 12-month period beginning on the date of grant.
Unvested options expire upon resignation or termination from the
Board.
|
|
·
|
In
addition, each Audit Committee member shall be eligible to receive a
nonqualified stock option for up to an aggregate of 15,000 shares per year
based the number of Audit Committee meetings attended by the Audit
Committee member during the year. The option exercise prices shall be
equal to the closing price of the Common Stock on the grant date. The
options shall have 10-year terms and vest, as long as the director remains
on the Board, on a monthly basis over a 12-month period beginning on the
date of grant. Unvested options expire upon resignation or termination
from the Board.
|
Name
|
Number of
Securities
Underlying
Unexercised Options
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
|
Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options Option
Awards
|
|||||||||
David
C. Cavalier
|
146,064 | 26,686 | — | |||||||||
John
M. Farah, Jr., Ph.D.
|
111,155 | 20,436 | — | |||||||||
Joseph
J. Krivulka
|
121,626 | 13,124 | — | |||||||||
Amit
Kumar, Ph.D.
|
147,064 | 26,686 | — | |||||||||
Michael
E. Lewis, Ph.D.
|
126,126 | 28,874 | — | |||||||||
Chris
A. Rallis
|
147,064 | 26,686 | — | |||||||||
Peter
D. Suzdak, Ph.D.
|
134,564 | 20,436 | — |
Plan category
|
(a)Number of securities to
be issued upon exercise of
outstanding options,
warrants and rights
|
(b)Weighted-average
exercise price of
outstanding options,
warrants and rights
|
(c)Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
|
|||||||||
Equity
compensation plans approved by our stockholders:
|
||||||||||||
2004
Stock Option Plan
|
4,249,091 | $ | 0.53 | 750,909 | ||||||||
1994
Stock Option Plan
|
1,927,124 | $ | 3.92 | 0 | ||||||||
Equity
compensation plans and securities not approved by our
stockholders:
|
||||||||||||
Warrant
to Purchase Common Stock Issued to Dan Delmonico
|
50,000 | $ | 0.49 |
Not
applicable
|
||||||||
Warrant
to Purchase Common Stock Issued to Brookstreet Securities
Corporation
|
250,000 | $ | 1.50 |
Not
applicable
|
||||||||
Total
– Common Stock
|
6,476,215 | 750,909 | ||||||||||
Convertible
Promissory Note convertible into shares of Series B Preferred Stock Issued
to ElanPharma International Limited (as of September 30,
2009)(1)(2)
|
65,985 | $ | 9.00 | 10,614 | ||||||||
Total
– Series B Preferred Stock
|
65,985 | 10,614 |
Name and Principal
|
Fiscal
|
Annual Compensation
|
All Other
|
|||||||||||||||||||
Position(s)
|
Year
|
Salary ($)
|
Bonus ($)
|
Option
Awards ($) (1)
|
Compensation
($)
|
Total ($)
|
||||||||||||||||
John
L. McManus
|
2009
|
$ | 250,200 | — | $ | 142,759 | — | $ | 392,958 | |||||||||||||
President
and
|
2008
|
$ | 250,200 | — | $ | 150,313 | — | $ | 400,513 | |||||||||||||
Chief
Executive Officer
|
2007
|
250,200 | — | 207,044 | — | 457,244 | ||||||||||||||||
Brian
Day, Ph.D. (2)
|
2009
|
— | — | 38,056 | $ | 132,000 | 170,056 | |||||||||||||||
Chief
Scientific Officer
|
2008
|
— | — | 31,899 | $ | 132,000 | 163,899 | |||||||||||||||
2007
|
— | — | 33,915 | 132,000 | 165,915 | |||||||||||||||||
Michael
P. McManus (3)
|
2009
|
— | — | 31,423 | — | 31,423 | ||||||||||||||||
Chief
Financial Officer,
|
2008
|
— | — | 77,110 | — | 77,110 | ||||||||||||||||
Treasurer
and Secretary
|
2007
|
— | — | 81,734 | — | 81,734 |
(1)
|
The
amounts in the “Option Awards” column reflect the dollar amounts
recognized as compensation expense for financial statements reporting
purposes for stock options for the fiscal year ended September 30, 2009 in
accordance with SFAS 123R. The assumptions we used to calculate
these amounts are discussed in Note H to our consolidated financial
statements included in our Annual Report on Form 10-K for the year ended
September 30, 2009.
|
(2)
|
Dr.
Day is Professor of Medicine, Immunology & Pharmaceutical Sciences at
the National Jewish Health (“NJH”) and is not an employee of the Company.
For his services as Chief Scientific Officer during fiscal 2007, 2008 and
2009, Dr. Day was paid a monthly consulting fee of $11,000. Dr.
Day also receives an option to purchase up to 50,000 shares of Common
Stock on October 1st of each year that he provides consulting services to
the Company. Dr. Day was paid $132,000 in consulting fees in
each of fiscal 2007, fiscal 2008 and fiscal 2009. In addition,
Dr. Day was granted an option to purchase up to 25,000 and 200,000 shares
of Common Stock on January 11, 2008 and May 6, 2009,
respectively. The Company has also entered into several grant
agreements with NJH, for which Dr. Day was the principal
investigator. The Company paid NJH $49,640, $65,280 and $23,273
in fiscal 2007, 2008 and 2009, respectively. The Company also has an
exclusive worldwide license from NJH to develop, make, have made, use and
sell products using certain technology developed by certain scientists at
NJH.
|
(3)
|
Mr.
Michael McManus was not an employee of the Company. For his services as
Chief Financial Officer, McManus & Company, Inc., a consulting firm in
which Mr. Michael McManus was an employee and is owned by Mr. John
McManus, was paid a monthly consulting payment of $25,000. Under this
contract, McManus & Company, Inc. also provides the Company with its
corporate headquarters, facilities management and the outsourcing of the
administrative, accounting, finance and accounting
functions. McManus & Company, Inc. was paid $335,000,
$300,000 and $300,000 in consulting fees pursuant to services rendered to
the Company in fiscal 2007, 2008 and 2009,
respectively.
|
Name
|
Grant Date
|
All Other Option Awards:
Number of Shares
Underlying Options (#)(2)
|
Exercise or
Base Price
of Option
Awards
|
Grant Date
Fair Value of
Option
Awards ($)
(1)
|
||||||||||
John L. McManus
|
5/6/09
|
1,000,000 | $ | 0.30 | $ | 266,800 | ||||||||
7/30/09
|
250,000 | $ | 0.39 | 86,800 | ||||||||||
Brian
Day, Ph.D.
|
10/1/2008
|
50,000 | $ | 0.44 | $ | 21,500 | ||||||||
5/6/2009
|
200,000 | $ | 0.30 | $ | 53,360 | |||||||||
Michael
P. McManus
|
7/10/2009
|
90,000 | $ | 0.39 | $ | 31,185 |
(1)
|
The
amounts in the “Grant Date Fair Value of Option Awards” column reflect the
grant date fair value of each equity award calculated in accordance with
SFAS 123(R).
|
(2)
|
The
option grant vests on a monthly basis for twelve months with a ten-year
term, subject to earlier termination upon certain
events.
|
Name
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
|
Option Awards
Equity Incentive Plan
Awards: Number of
Securities Underlying
Unexercised Unearned
Options
|
Option
Exercise Price
|
Option
Expiration
Date
|
||||||||||||
John
L. McManus
|
10,000 | — | — | $ | 0.97 |
7/29/2015
|
|||||||||||
10,000 | — | — | $ | 0.91 |
8/31/2015
|
||||||||||||
10,000 | — | — | $ | 1.12 |
9/30/2015
|
||||||||||||
10,000 | — | — | $ | 1.15 |
10/31/2015
|
||||||||||||
10,000 | — | — | $ | 1.03 |
11/30/2015
|
||||||||||||
10,000 | — | — | $ | 0.95 |
12/30/2015
|
Name
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
Number of Securities
Underlying
Unexercised
Options
Unexercisable
|
Option Awards
Equity Incentive Plan
Awards: Number of
Securities Underlying
Unexercised Unearned
Options
|
Option
Exercise Price
|
Option
Expiration
Date
|
||||||||||||
10,000 | — | — | $ | 0.89 |
1/31/2016
|
||||||||||||
10,000 | — | — | $ | 0.90 |
2/28/2016
|
||||||||||||
10,000 | — | — | $ | 0.80 |
3/31/2016
|
||||||||||||
10,000 | — | — | $ | 0.75 |
4/28/2016
|
||||||||||||
10,000 | — | — | $ | 0.60 |
5/31/2016
|
||||||||||||
10,000 | — | — | $ | 0.81 |
6/30/2016
|
||||||||||||
250,000 | — | — | $ | 0.75 |
7/14/2016
|
||||||||||||
250,000 | — | — | $ | 0.90 |
7/13/2017
|
||||||||||||
250,000 | — | — | $ | 0.32 |
7/14/2018
|
||||||||||||
500,000 | 500,000 | (1) | — | $ | 0.30 |
5/6/2019
|
|||||||||||
62,500 | 187,500 | (2) | — | $ | 0.39 |
7/30/2019
|
|||||||||||
Brian
Day, Ph.D.
|
1,200 | — | — | $ | 51.25 |
4/7/2010
|
|||||||||||
2,000 | — | — | $ | 0.90 |
2/28/2015
|
||||||||||||
2,000 | — | — | $ | 0.70 |
3/31/2015
|
||||||||||||
2,000 | — | — | $ | 0.55 |
4/29/2015
|
||||||||||||
2,000 | — | — | $ | 0.71 |
5/31/2015
|
||||||||||||
2,000 | — | — | $ | 0.73 |
6/30/2015
|
||||||||||||
2,000 | — | — | $ | 0.97 |
7/29/2015
|
||||||||||||
2,000 | — | — | $ | 0.91 |
8/31/2015
|
||||||||||||
2,000 | — | — | $ | 1.12 |
9/30/2015
|
||||||||||||
2,000 | — | — | $ | 1.15 |
10/31/2015
|
||||||||||||
2,000 | — | — | $ | 1.03 |
11/30/2015
|
||||||||||||
2,000 | — | — | $ | 0.95 |
12/31/2015
|
||||||||||||
2,000 | — | — | $ | 0.89 |
1/31/2016
|
||||||||||||
2,000 | — | — | $ | 0.90 |
2/28/2016
|
||||||||||||
2,000 | — | — | $ | 0.80 |
3/31/2016
|
||||||||||||
2,000 | — | — | $ | 0.75 |
4/28/2016
|
||||||||||||
2,000 | — | — | $ | 0.60 |
5/31/2016
|
||||||||||||
25,000 | — | — | $ | 0.85 |
6/5/2016
|
||||||||||||
2,000 | — | — | $ | 0.81 |
6/30/2016
|
||||||||||||
2,000 | — | — | $ | 0.69 |
7/31/2016
|
||||||||||||
2,000 | — | — | $ | 0.80 |
8/31/2016
|
||||||||||||
2,000 | — | — | $ | 0.80 |
9/29/2016
|
||||||||||||
50,000 | — | — | $ | 0.68 |
10/2/2016
|
||||||||||||
50,000 | — | — | $ | 0.45 |
10/1/2017
|
||||||||||||
25,000 | — | — | $ | 0.40 |
1/11/2018
|
||||||||||||
50,000 | — | (3) | — | $ | 0.44 |
10/1/2018
|
|||||||||||
100,000 | 100,000 | (1) | — | $ | 0.30 |
5/6/2019
|
|||||||||||
Michael
P. McManus
|
1,250 | — | — | $ | 0.73 |
6/30/2015
|
|||||||||||
1,250 | — | — | $ | 0.97 |
7/29/2015
|
||||||||||||
1,250 | — | — | $ | 0.91 |
8/31/2015
|
||||||||||||
1,250 | — | — | $ | 1.12 |
9/30/2015
|
||||||||||||
1,250 | — | — | $ | 1.15 |
10/31/2015
|
||||||||||||
1,250 | — | — | $ | 1.03 |
11/30/2015
|
||||||||||||
1,250 | — | — | $ | 0.95 |
12/30/2015
|
||||||||||||
1,250 | — | — | $ | 0.89 |
1/31/2016
|
||||||||||||
1,250 | — | — | $ | 0.90 |
2/28/2016
|
Name
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
Number of Securities
Underlying
Unexercised
Options
Unexercisable
|
Option Awards
Equity Incentive Plan
Awards: Number of
Securities Underlying
Unexercised Unearned
Options
|
Option
Exercise Price
|
Option
Expiration
Date
|
||||||||||||
1,250 | — | — | $ | 0.80 |
3/31/2016
|
||||||||||||
1,250 | — | — | $ | 0.75 |
4/28/2016
|
||||||||||||
1,250 | — | — | $ | 0.60 |
5/31/2016
|
||||||||||||
1,250 | — | — | $ | 0.81 |
6/30/2016
|
||||||||||||
90,000 | — | — | $ | 0.80 |
7/10/2016
|
||||||||||||
90,000 | — | — | $ | 1.01 |
7/10/2017
|
||||||||||||
45,000 | — | — | $ | 0.40 |
1/11/2018
|
||||||||||||
90,000 | — | — | $ | 0.36 |
7/10/2018
|
||||||||||||
30,000 | 60,000 | (4) | — | $ | 0.39 |
7/10/2019
|
(1)
|
This
option vests as to these shares in approximately equal monthly
installments through May 6, 2010.
|
(2)
|
This
option vests as to these shares in approximately equal monthly
installments through July 30, 2010.
|
(3)
|
The
remaining shares subject to this option vested on October 1, 2009 and are
fully exercisable.
|
(4)
|
This
option vests as to these shares in approximately equal monthly
installments through July 10, 2010.
|
Name
|
Grant Date
|
All Other Option Awards:
Number of Shares
Underlying Options (#) (2)
|
Exercise or
Base Price
of Option
Awards
|
Grant Date
Fair Value of
Option
Awards ($)
(1)
|
||||||||||
David
C. Cavalier
|
12/11/2008
|
27,750 | $ | 0.40 | $ | 11,086 | ||||||||
2/5/2009
|
3,750 | 0.29 | 1,086 | |||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
4/30/2009
|
3,750 | 0.38 | 1,268 | |||||||||||
6/4/2009
|
11,250 | 0.35 | ]3,515 | |||||||||||
7/30/2009
|
15,000 | 0.39 | 5,208 | |||||||||||
John
M. Farah, Jr., Ph.D.
|
12/11/2008
|
20,250 | 0.40 | 8,090 | ||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
6/4/2009
|
11,250 | 0.35 | 3,515 | |||||||||||
7/30/2009
|
11,250 | 0.39 | 3,906 | |||||||||||
Joseph
J. Krivulka
|
12/11/2008
|
11,250 | 0.40 | 4,494 | ||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
7/30/2009
|
11,250 | 0.39 | 3,906 | |||||||||||
Amit
Kumar, Ph.D.
|
12/11/2008
|
27,750 | 0.40 | 11,086 | ||||||||||
2/5/2009
|
3,750 | 0.29 | 1,086 | |||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
4/30/2009
|
3,750 | 0.38 | 1,268 | |||||||||||
6/4/2009
|
11,250 | 0.35 | 3,515 | |||||||||||
7/30/2009
|
15,000 | 0.39 | 5,208 | |||||||||||
Michael
E. Lewis, Ph.D.
|
12/11/2008
|
9,000 | 0.40 | 3,596 | ||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
6/4/2009
|
11,250 | 0.35 | 3,515 | |||||||||||
7/30/2009
|
11,250 | 0.39 | 3,906 | |||||||||||
Chris
A. Rallis
|
12/11/2008
|
27,750 | 0.40 | 11,086 | ||||||||||
2/5/2009
|
3,750 | 0.29 | 1,086 | |||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
4/30/2009
|
3,750 | 0.38 | 1,268 | |||||||||||
6/4/2009
|
11,250 | 0.35 | 3,515 | |||||||||||
7/30/2009
|
15,000 | 0.39 | 5,208 | |||||||||||
Peter
D. Suzdak, Ph.D.
|
12/11/2008
|
20,250 | 0.40 | 8,090 | ||||||||||
3/26/2009
|
11,250 | 0.33 | 3,709 | |||||||||||
6/4/2009
|
11,250 | 0.35 | 3,515 | |||||||||||
7/30/2009
|
11,250 | 0.39 | 3,906 |
(1)
|
The
amounts in the “Grant Date Fair Value of Option Awards” column reflect the
grant date fair value of each equity award calculated in accordance with
SFAS 123(R).
|
(2)
|
All
option grants to Directors vests on a monthly basis for twelve months from
the date of grant with a ten-year term, subject to earlier termination
upon certain events.
|
Termination
without Cause or for Good Reason
|
Voluntary
Resignation
|
|||||||||||||||||||
Value
of Options
|
Value
of Stock
|
|||||||||||||||||||
Cash
|
Value
of
|
with
Accelerated
|
with
Accelerated
|
Cash
|
||||||||||||||||
Name
|
Payments(1)
|
Benefits(2)
|
Vesting(3)
|
Vesting(4)
|
Payments
|
|||||||||||||||
John
L. McManus
|
$ |
187,650
|
$ |
19,689
|
$ |
45,000
|
—
|
—
|
||||||||||||
Brian
Day, Ph.D.
|
11,000
|
—
|
9,000
|
—
|
—
|
|||||||||||||||
Michael
P. McManus
|
225,000
|
—
|
—
|
—
|
—
|
Immediately
upon a Change of Control
|
Termination
in Connection with a Change of Control
|
|||||||||||||||||||||||
Value
of Options
|
Value
of Options
|
Value
of Stock
|
||||||||||||||||||||||
Cash
|
with
Accelerated
|
Cash
|
Value
of
|
with
Accelerated
|
with
Accelerated
|
|||||||||||||||||||
Name
|
Payments
(5)
|
Vesting(3)
|
Payments(1)
|
Benefits(2)
|
Vesting(3)
|
Vesting(4)
|
||||||||||||||||||
John
L. McManus
|
$ |
100,000
|
$
|
$45,000
|
$
|
187,650
|
$
|
19,689
|
$
|
$45,000
|
—
|
|||||||||||||
Brian
Day, Ph.D. (6)
|
30,000
|
9,000
|
11,000
|
—
|
9,000
|
—
|
||||||||||||||||||
Michael
P. McManus
|
50,000
|
—
|
225,000
|
—
|
$ |
45,000
|
—
|
(1)
|
The
amounts in this column reflect a lump sum payment equal to the remaining
term of the executive officer’s employment or consulting agreement in
effect on September 30, 2009 assuming notice of termination was given on
September 30, 2009.
|
(2)
|
The
amounts in this column reflect the estimated value of health, dental, life
and disability insurance to be provided to the Named Executive Officer
subsequent to a termination.
|
(3)
|
The
amounts in this column are calculated based on the difference between
$0.39, the closing market price per share of our common stock on September
30, 2009, and the exercise price per share of the options subject to
accelerated vesting.
|
(4)
|
The
amounts in this column are calculated by multiplying the number of shares
subject to accelerated vesting by $0.39, the closing market price per
share of our common stock on September 30,
2009.
|
(5)
|
The
amounts in this column reflect the lump sum payment payable upon a change
of control pursuant to the executive officer’s employment or consulting
agreement in effect on September 30, 2009 assuming a change of control
occurred on September 30,
2009.
|
(6)
|
Dr.
Day would also be granted a stock option to purchase 25,000 shares of the
Company’s Common Stock with an exercise price equal to the closing stock
price on the date of grant upon the occurrence of a change of
control.
|
|
·
|
the date on which shares of
common stock are first purchased pursuant to a tender offer or exchange
offer;
|
|
·
|
the date the Company acquires
knowledge that any person or group has become the beneficial owner of
securities of the Company entitling the person or group to 30% or more of
all votes to which all stockholders of the Company would be entitled in
the election of the Board of Directors were an election held on such
date;
|
|
·
|
the date, during any period of
two consecutive years, when individuals who at the beginning of such
period constitute the Board of Directors of the Company cease for any
reason to constitute at least a majority thereof;
and
|
|
·
|
the date on which our
stockholders approve an agreement for a merger or sale of substantially
all of our assets.
|
Total
|
||||
Fiscal
Year 2009
|
||||
Audit
Fees (1)
|
$ | 67,090 | ||
Audit-Related
Fees (2)
|
1,500 | |||
Tax
Fees
|
— | |||
All
Other Fees
|
— | |||
Total
Fiscal Year 2009
|
$ | 68,590 | ||
Fiscal
Year 2008
|
||||
Audit
Fees (1)
|
$ | 68,650 | ||
Audit-Related
Fees (2)
|
3,300 | |||
Tax
Fees
|
— | |||
All
Other Fees
|
— | |||
Total
Fiscal Year 2008
|
$ | 71,950 |
Submitted
by:
|
The
Audit Committee
|
|
David
C. Cavalier, Chairman
|
||
Amit
Kumar, Ph.D.
|
||
Chris
A. Rallis
|
Name of Stockholder
|
Authorized
Signature Name
|
Number of Shares
Common Stock held as
at
January 25, 2010
|
Signature
|
||||
Xmark
Opportunity Fund, L.P.
By:
Xmark Opportunity GP, LLC, Its General Partner
By:
Xmark Opportunity Partners, LLC, its Sole Member
By:
Xmark Capital Partners, LLC, its Managing Member
|
Mitchell
D. Kaye
Co-Managing
Member
|
6,680,829 |
/s/
Mitchell D. Kaye
|
||||
Xmark
Opportunity Fund, Ltd.
By:
Xmark Opportunity Manager, LLC, Its Investment Manager
By:
Xmark Opportunity Partners, LLC, its Sole Member
By:
Xmark Capital Partners, LLC, its Managing Member
|
Mitchell
D. Kaye
Co-Managing
Member
|
13,753,871 |
/s/
Mitchell D. Kaye
|
||||
XmarkJV
Investment Partners, LLC
By:
Xmark Opportunity Manager, LLC, Its Investment Manager
By:
Xmark Capital Partners, LLC, its Managing Member
|
Mitchell
D. Kaye
Co-Managing
Member
|
1,023,731 |
/s/
Mitchell D. Kaye
|
||||
Xmark
Opportunity Fund, L.P.
By:
Xmark Opportunity GP, LLC, Its General Partner
By:
Xmark Opportunity Partners, LLC, its Sole Member
By:
Xmark Capital Partners, LLC, its Managing Member
|
Mitchell
D. Kaye
|
1,000,000 |
/s/
Mitchell D. Kaye
|
||||
Goodnow
Capital, L.L.C.
By:
Xmark Opportunity GP, LLC, Its General Partner
By:
Xmark Opportunity Partners, LLC, its Sole
Member
By:
Xmark Capital Partners, LLC, its Managing
Member
|
David
C. Cavalier
|
8,107,039 |
/s/
David C. Cavalier
|
||||
Total
Shares Voting in Favor:
|
30,565,470 |
of 48,264,320
shares of common stock issued and outstanding as at January 25, 2010, the
effective date of these resolutions
|
|||||
Percentage
of Common Stock
Voting
in Favor of Resolutions :
|
63.3 | % |
I.
|
PURPOSE
|
1.
|
The
primary function of the Audit Committee (“Committee”) of Aeolus
Pharmaceuticals, Inc. (the “Company”) is to assist the Board of Directors
(“Board”) in fulfilling its oversight responsibilities related to
corporate accounting, financial reporting practices, quality and integrity
of financial reports as well as legal compliance and business ethics
matters. It shall be the policy of the Committee to maintain
free and open communication between the Board, the independent auditors
and the management of the Company.
|
2.
|
Although
the Committee has the responsibilities and powers set forth in this
charter, it is not the duty of the Committee to plan or conduct audits or
to determine that the Company’s financial statements are complete and
accurate and are in accordance with generally accepted accounting
principles. This is the responsibility of management and the
independent auditors. Nor is it the duty of the Committee to
conduct investigations, to resolve disagreements, if any, between
management and the independent auditors or to assure compliance with laws
and regulations and the Company’s
policies.
|
II.
|
ORGANIZATION
|
1.
|
Members - The Committee
shall be composed of directors who are independent of the management of
the Company and are free of any relationship that, in the opinion of the
Board, would interfere with their exercise of independent judgment as a
Committee member. Committee members shall be appointed by the
Board, and (after June 13, 2001) the Committee shall be composed of not
less than three independent Directors who are financially
literate. At least one member of the Committee shall have
accounting or related financial management
expertise.
|
2.
|
Meetings - The Committee
should meet on a regular basis and special meetings should be called as
circumstances require. The Committee shall meet privately from
time to time with representatives of the Company’s independent public
accountants and management. Written minutes should be kept for
all meetings and the Committee will report to the Board after each
Committee meeting.
|
3.
|
Charter - The Board and
the Committee shall review the adequacy of the Audit Committee Charter on
an annual basis.
|
III.
|
FUNCTIONS
|
1.
|
Independent Accountants
- Recommend to the Board annually, the firm to be employed by the
Company as its independent accountants. Instruct the
independent accountants that they are ultimately responsible to the Board
and the Committee. Receive from the independent accountants a
formal written statement delineating all relationships between the
independent accountants and the Company, to ensure objectivity and
independence.
|
2.
|
Audit Plans & Results
- Review the plans, scope, fees and results for the annual audit
with the independent auditors. Meet with management and the
independent auditors together and separately to discuss the financial
statements and the results of the audit. Inquire of management
and the independent auditor if any significant financial reporting issues
arose during the current audit and, if so, how they were
resolved. Evaluate and recommend to the Board whether or not
the annual audited financial statements should be filed with the SEC on
Form 10-K. Discuss any significant issues, if any, raised by
the independent auditors in their letter of recommendations to management
regarding internal control weaknesses and process
improvements. Also review the extent of any services and fees
outside the audit area performed for the Company by its independent
accountants.
|
3.
|
Accounting Principles and
Disclosures - Review significant developments in accounting rules
and recommended changes in the Company’s methods of accounting or
financial statements. The Committee also shall review with the
independent accountants the quality and acceptability of the application
of the Company’s accounting principles to the Company’s financial
reporting, including any significant proposed changes in accounting
principles and financial
statements.
|
4.
|
Internal Accounting
Controls - Consult with the independent accountants regarding the
adequacy of internal accounting controls. Inquire as to the
adequacy of the Company’s accounting, financial and auditing personnel
resources. As appropriate, consultation with the independent
accountants regarding internal controls should be conducted out of
management’s presence.
|
5.
|
Internal Control Systems
- Review with management and the Company’s internal control systems
intended to ensure the reliability of financial reporting and compliance
with applicable codes of conduct, laws and regulations. Special
presentations may be requested of Company personnel responsible for such
areas as legal, human resources, information technology, environmental,
risk management, tax compliance and others as considered
appropriate.
|
6.
|
Interim Financial
Statements - Review how management develops and summarizes
quarterly financial information. Require the independent
auditors review the quarterly financial information to be included in the
Company’s Form 10-Q.
|